Photosensitization in Porphyrias and Photodynamic Therapy Involves TRPA1 and TRPV1

• Published in: The Journal of neuroscience Vol. 36; no. 19; pp. 5264 - 5278
• Main Authors: Babes, Alexandru, Sauer, Susanne K., Moparthi, Lavanya, Kichko, Tatjana I., Neacsu, Cristian, Namer, Barbara, Filipovic, Milos, Zygmunt, Peter M., Reeh, Peter W., Fischer, Michael J. M.
• Format: Journal Article
• Language: English
• Published: United States Society for Neuroscience 11.05.2016
• Subjects: Aminolaevulinic acid; Aminolevulinic Acid - pharmacology; Animals; Cells, Cultured; Clinical Medicine; HEK293 Cells; Humans; Klinisk medicin; Medical and Health Sciences; Medicin och hälsovetenskap; Mice; Mice, Inbred C57BL; Neurologi; Neurology; Neuropeptides - metabolism; Pain; Photochemotherapy; Photosensitizing Agents - pharmacology; Porphyrias - metabolism; Porphyrias - therapy; Protoporphyrin IX; Protoporphyrins - pharmacology; Reactive Oxygen Species - metabolism; Sensory Receptor Cells - metabolism; Skin - drug effects; Skin - radiation effects; Transient Receptor Potential Channels - metabolism; TRPA1 Cation Channel; TRPV Cation Channels - metabolism; aminolaevulinic acid; pain; protoporphyrin IX

Photosensitization, an exaggerated sensitivity to harmless light, occurs genetically in rare diseases, such as porphyrias, and in photodynamic therapy where short-term toxicity is intended. A common feature is the experience of pain from bright light. In human subjects, skin exposure to 405 nm light...